What Researchers Did
The researchers discussed the current challenges and limitations of hyperbaric oxygen therapy (HBO2T) in treating chronic wounds and diabetic foot ulcers (DFU), particularly regarding patient selection and treatment efficacy.
What They Found
They found that non-healing wounds represent a significant public health concern, costing over $25 billion annually in the US, with hyperbaric oxygen therapy (HBO2T) being a costly mainstay treatment. Despite its use, 30-40% of diabetic foot ulcer patients with severe ulcers fail to heal by 24 weeks, often after receiving 30-60 daily treatments over 6-10 weeks, due to inaccurate responder identification methods.
What This Means for Canadian Patients
Canadian patients with chronic wounds, especially diabetic foot ulcers, may face similar challenges regarding the high cost and variable effectiveness of hyperbaric oxygen therapy (HBO2T). Improved methods for identifying patients who will benefit from HBO2T are crucial to avoid prolonged, expensive, and ineffective treatments.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
The abstract does not present novel research data or specific solutions to the identified challenges in hyperbaric oxygen therapy patient selection.